Baidu
map

中国急性血栓性疾病抗栓治疗共识

2019-06-25 中国医药教育协会 中国急救医学杂志.2019.39(6):501-532.

急性血栓性疾病是临床常见的一大类急症,属于急性非创伤性血管急症的范畴;按照累及的血管系统分类可分为动脉系统血栓栓塞和静脉系统血栓栓塞,按照解剖器官分类可以分为头颈部血栓栓塞、胸部血栓栓塞、腹部血栓栓塞、肢体血栓栓塞等。动脉系统血栓栓塞表现为受累血管支配的相应器官缺血,甚至坏死,及时的血管再灌注治疗可以挽救相应器官,也直接影响患者的预后;静脉系统血栓栓塞包括肺栓塞和深静脉血栓(DVT),表现为受累静

中文标题:

中国急性血栓性疾病抗栓治疗共识

发布机构:

中国医药教育协会

发布日期:

2019-06-25

简要介绍:

急性血栓性疾病是临床常见的一大类急症,属于急性非创伤性血管急症的范畴;按照累及的血管系统分类可分为动脉系统血栓栓塞和静脉系统血栓栓塞,按照解剖器官分类可以分为头颈部血栓栓塞、胸部血栓栓塞、腹部血栓栓塞、肢体血栓栓塞等。动脉系统血栓栓塞表现为受累血管支配的相应器官缺血,甚至坏死,及时的血管再灌注治疗可以挽救相应器官,也直接影响患者的预后;静脉系统血栓栓塞包括肺栓塞和深静脉血栓(DVT),表现为受累静脉的回流障碍,DVT血栓脱落后表现为肺血管栓塞,重者可危及生命,需要在时间窗内给予再灌注治疗。目前国内外尚缺乏针对急性血栓性疾病抗栓治疗的共识或者指南。因此,中华医学会急诊医学分会和中国医药教育协会急诊医学分会组织相关领域专家组成共识编制组,共同编制了《中国急性血栓性疾病抗栓治疗共识》,旨在规范并提升临床医师对急性血栓疾病的诊断和抗栓治疗的实践能力,为进一步开展临床实践和相关研究提供指导意见。 

拓展指南:血栓相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国急性血栓性疾病抗栓治疗共识)] GetToolGuiderByIdResponse(projectId=1, id=a683c1c001e552ad, title=中国急性血栓性疾病抗栓治疗共识, enTitle=, guiderFrom=中国急救医学杂志.2019.39(6):501-532., authorId=null, author=, summary=急性血栓性疾病是临床常见的一大类急症,属于急性非创伤性血管急症的范畴;按照累及的血管系统分类可分为动脉系统血栓栓塞和静脉系统血栓栓塞,按照解剖器官分类可以分为头颈部血栓栓塞、胸部血栓栓塞、腹部血栓栓塞、肢体血栓栓塞等。动脉系统血栓栓塞表现为受累血管支配的相应器官缺血,甚至坏死,及时的血管再灌注治疗可以挽救相应器官,也直接影响患者的预后;静脉系统血栓栓塞包括肺栓塞和深静脉血栓(DVT),表现为受累静, cover=, journalId=null, articlesId=null, associationId=1778, associationName=中国医药教育协会, associationIntro=, copyright=0, guiderPublishedTime=Tue Jun 25 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>急性血栓性疾病是临床常见的一大类急症,属于急性非创伤性血管急症的范畴;按照累及的血管系统分类可分为动脉系统血栓栓塞和静脉系统血栓栓塞,按照解剖器官分类可以分为头颈部血栓栓塞、胸部血栓栓塞、腹部血栓栓塞、肢体血栓栓塞等。动脉系统血栓栓塞表现为受累血管支配的相应器官缺血,甚至坏死,及时的血管再灌注治疗可以挽救相应器官,也直接影响患者的预后;静脉系统血栓栓塞包括肺栓塞和深静脉血栓(DVT),表现为受累静脉的回流障碍,DVT血栓脱落后表现为肺血管栓塞,重者可危及生命,需要在时间窗内给予再灌注治疗。目前国内外尚缺乏针对急性血栓性疾病抗栓治疗的共识或者指南。因此,中华医学会急诊医学分会和中国医药教育协会急诊医学分会组织相关领域专家组成共识编制组,共同编制了《中国急性血栓性疾病抗栓治疗共识》,旨在规范并提升临床医师对急性血栓疾病的诊断和抗栓治疗的实践能力,为进一步开展临床实践和相关研究提供指导意见。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>血栓</font>相关指南:</strong><br><ul><li><a href="//m.capotfarm.com/guideline/show_article.do?id=80f951c001e3a562" title="2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗" target=_blank>2019 ESO指南:卒中或短暂性脑缺血发作以及非瓣膜性房颤患者卒中和其他血栓栓塞事件二级预防抗栓治疗</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=f24921c001e122b4" title="2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术" target=_blank>2019 ESO/ESMINT指南:急性缺血性卒中机械血栓清除术</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=70bea1c001e0a54c" title="2019 THANZ指南:静脉血栓栓塞的诊断和管理" target=_blank>2019 THANZ指南:静脉血栓栓塞的诊断和管理</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=9721f1c00169e128" title="《中国心肺复苏专家共识》之静脉血栓栓塞性CA指南" target=_blank>《中国心肺复苏专家共识》之静脉血栓栓塞性CA指南</a></li> <li><a href="//m.capotfarm.com/guideline/show_article.do?id=c8e601c00168803b" title="2019 SNIS报告:急性缺血性卒中紧急大血管闭塞血栓切除术的适应证" target=_blank>2019 SNIS报告:急性缺血性卒中紧急大血管闭塞血栓切除术的适应证</a></li> 更多信息请点击:<a href="//m.capotfarm.com/guideline/list.do?q=%E8%A1%80%E6%A0%93" target=_blank>有关血栓更多指南</a></ul>, tagList=[TagDto(tagId=91605, tagName=急性血栓性疾病), TagDto(tagId=3301, tagName=抗栓治疗)], categoryList=[CategoryDto(categoryId=38, categoryName=急重症科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11811, appHits=829, showAppHits=2, pcHits=4633, showPcHits=8045, likes=88, shares=50, comments=23, approvalStatus=1, publishedTime=Sat Jun 29 10:08:36 CST 2019, publishedTimeString=2019-06-25, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sat Jun 29 10:08:36 CST 2019, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:05:11 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国急性血栓性疾病抗栓治疗共识)])
中国急性血栓性疾病抗栓治疗共识
下载请点击:
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1059149, encodeId=768e1059149a0, content=好东西!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb232390492, createdName=hbn1987, createdTime=Sun Oct 10 11:37:14 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055755, encodeId=6ad21055e5515, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cdf5306918, createdName=1487b89em13暂无昵称, createdTime=Tue Sep 28 17:04:05 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007478, encodeId=b190100e47852, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/beecb740bfb247b5af86be0c6c721d46/a4de252e6a65478f9b7851366a5a10a9.jpg, createdBy=72024184433, createdName=拼搏的老马, createdTime=Fri Aug 13 06:56:54 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966100, encodeId=f994966100d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210516/f87e86262a2c45248fb3b19f68a93e9f/463c650bcb9145b3a632e70d6944ab06.jpg, createdBy=395d5502666, createdName=wu莫愁, createdTime=Sun May 16 21:59:43 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960072, encodeId=06699600e259, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sat Apr 24 17:35:21 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2021-10-10 hbn1987

    好东西!

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1059149, encodeId=768e1059149a0, content=好东西!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb232390492, createdName=hbn1987, createdTime=Sun Oct 10 11:37:14 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055755, encodeId=6ad21055e5515, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cdf5306918, createdName=1487b89em13暂无昵称, createdTime=Tue Sep 28 17:04:05 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007478, encodeId=b190100e47852, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/beecb740bfb247b5af86be0c6c721d46/a4de252e6a65478f9b7851366a5a10a9.jpg, createdBy=72024184433, createdName=拼搏的老马, createdTime=Fri Aug 13 06:56:54 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966100, encodeId=f994966100d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210516/f87e86262a2c45248fb3b19f68a93e9f/463c650bcb9145b3a632e70d6944ab06.jpg, createdBy=395d5502666, createdName=wu莫愁, createdTime=Sun May 16 21:59:43 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960072, encodeId=06699600e259, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sat Apr 24 17:35:21 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2021-09-28 1487b89em13暂无昵称

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1059149, encodeId=768e1059149a0, content=好东西!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb232390492, createdName=hbn1987, createdTime=Sun Oct 10 11:37:14 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055755, encodeId=6ad21055e5515, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cdf5306918, createdName=1487b89em13暂无昵称, createdTime=Tue Sep 28 17:04:05 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007478, encodeId=b190100e47852, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/beecb740bfb247b5af86be0c6c721d46/a4de252e6a65478f9b7851366a5a10a9.jpg, createdBy=72024184433, createdName=拼搏的老马, createdTime=Fri Aug 13 06:56:54 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966100, encodeId=f994966100d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210516/f87e86262a2c45248fb3b19f68a93e9f/463c650bcb9145b3a632e70d6944ab06.jpg, createdBy=395d5502666, createdName=wu莫愁, createdTime=Sun May 16 21:59:43 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960072, encodeId=06699600e259, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sat Apr 24 17:35:21 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2021-08-13 拼搏的老马

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1059149, encodeId=768e1059149a0, content=好东西!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb232390492, createdName=hbn1987, createdTime=Sun Oct 10 11:37:14 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055755, encodeId=6ad21055e5515, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cdf5306918, createdName=1487b89em13暂无昵称, createdTime=Tue Sep 28 17:04:05 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007478, encodeId=b190100e47852, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/beecb740bfb247b5af86be0c6c721d46/a4de252e6a65478f9b7851366a5a10a9.jpg, createdBy=72024184433, createdName=拼搏的老马, createdTime=Fri Aug 13 06:56:54 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966100, encodeId=f994966100d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210516/f87e86262a2c45248fb3b19f68a93e9f/463c650bcb9145b3a632e70d6944ab06.jpg, createdBy=395d5502666, createdName=wu莫愁, createdTime=Sun May 16 21:59:43 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960072, encodeId=06699600e259, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sat Apr 24 17:35:21 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2021-05-16 wu莫愁

    good

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1059149, encodeId=768e1059149a0, content=好东西!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=125, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bb232390492, createdName=hbn1987, createdTime=Sun Oct 10 11:37:14 CST 2021, time=2021-10-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1055755, encodeId=6ad21055e5515, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1cdf5306918, createdName=1487b89em13暂无昵称, createdTime=Tue Sep 28 17:04:05 CST 2021, time=2021-09-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1007478, encodeId=b190100e47852, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210813/beecb740bfb247b5af86be0c6c721d46/a4de252e6a65478f9b7851366a5a10a9.jpg, createdBy=72024184433, createdName=拼搏的老马, createdTime=Fri Aug 13 06:56:54 CST 2021, time=2021-08-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=966100, encodeId=f994966100d0, content=good, beContent=null, objectType=guider, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210516/f87e86262a2c45248fb3b19f68a93e9f/463c650bcb9145b3a632e70d6944ab06.jpg, createdBy=395d5502666, createdName=wu莫愁, createdTime=Sun May 16 21:59:43 CST 2021, time=2021-05-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=960072, encodeId=06699600e259, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=128, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210424/75ca38f652414914af9cbfb5b446886f/ea6e0bf538564d608b3eecda251c149e.jpg, createdBy=58765422551, createdName=ms5000001465822468, createdTime=Sat Apr 24 17:35:21 CST 2021, time=2021-04-24, status=1, ipAttribution=)]
    2021-04-24 ms5000001465822468

    学习了

    0

Baidu
map
Baidu
map
Baidu
map